Brief Summary
This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician’s choice of chemotherapya cancer treatment that uses drugs to kill or slow the growth of cancer cells, while minimising damage to healthy cells (doxorubicin or paclitaxel) in participants with B7-H4 selected advancedat a late stage, far along/metastatic EC that progressed following platinum based chemotherapy and anti-PD-1/anti-PD-L1 therapy.
Intervention / Treatment
- Drug: Puxitatug Samrotecan
- Drug: Doxorubicin
- Drug: Paclitaxel
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Histologically confirmed diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of endometrial carcinomacancer arising from tissues that line organs or carcinosarcoma.
- Recurrent/metastatic EC ie, with radiological or objective evidence of recurrenceto occur or happen again or progression.
- Has received prior platinum-based chemotherapy and anti-programmed cell death 1 protein (PD-1)/anti- programmed cell death ligand 1 (PD-L1) therapy, either separately or in combination.
- A WHO/ECOG performance status of 0 or 1 at Screeningtesting for cancer or conditions that can lead to cancer before symptoms appear, also known as cancer screening.
- Has radiographically measurable disease by RECIST 1.1.